Activity of the Highly Specific RET Inhibitor Selpercatinib (LOXO-292) in Pediatric Patients With Tumors Harboring Gene Alterations

Overview

Journal JCO Precis Oncol

Specialty Oncology

Date 2020 Sep 14

PMID 32923911

Citations 20

Authors

Michael V Ortiz

Ulrike Gerdemann

Sandya Govinda Raju

Dahlia Henry

Steve Smith

S Michael Rothenberg

Michael C Cox

Stephanie Proust

Julia Glade Bender

A Lindsay Frazier

Peter Anderson

Alberto S Pappo

Affiliations

Soon will be listed here.

Citing Articles

Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives.

Zhang Y, Zheng W, Zhou S, Gu J, Yu Q, Zhu Y Cell Commun Signal. 2024; 22(1):460.

PMID: 39342195 PMC: 11439284. DOI: 10.1186/s12964-024-01837-x.

Exploiting frequent and specific expression of PRL3 in pediatric solid tumors for first-in-child use of PRL3-zumab humanized antibody.

Loh A, Thura M, Gupta A, Tan S, Kuan K, Ang K Mol Ther Oncolytics. 2023; 30:153-166.

PMID: 37674627 PMC: 10477756. DOI: 10.1016/j.omto.2023.08.006.

Targeting the RET tyrosine kinase in neuroblastoma: A review and application of a novel selective drug design strategy.

Steen E, Basilaia M, Kim W, Getz T, Gustafson J, Zage P Biochem Pharmacol. 2023; 216:115751.

PMID: 37595672 PMC: 10911250. DOI: 10.1016/j.bcp.2023.115751.

Intracranial Activity of Selpercatinib in Chinese Patients With Advanced Fusion-Positive Non-Small-Cell Lung Cancer in the Phase II LIBRETTO-321 Trial.

Cheng Y, Huang D, Zhou J, Zhou C, Sun Y, Wu L JCO Precis Oncol. 2023; 7:e2200708.

PMID: 37315261 PMC: 10309543. DOI: 10.1200/PO.22.00708.

Real-world performance analysis of a novel computational method in the precision oncology of pediatric tumors.

Vodicska B, Deri J, Tihanyi D, Varkondi E, Kispeter E, Doczi R World J Pediatr. 2023; 19(10):992-1008.

PMID: 36914906 PMC: 10497647. DOI: 10.1007/s12519-023-00700-2.

References

Wirth L, Kohno T, Udagawa H, Matsumoto S, Ishii G, Ebata K . Emergence and Targeting of Acquired and Hereditary Resistance to Multikinase RET Inhibition in Patients With RET-Altered Cancer. JCO Precis Oncol. 2020; 3. PMC: 7446343. DOI: 10.1200/PO.19.00189. View

Fenton C, Lukes Y, Nicholson D, Dinauer C, Francis G, Tuttle R . The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults. J Clin Endocrinol Metab. 2000; 85(3):1170-5. DOI: 10.1210/jcem.85.3.6472. View

Raue F, Frank-Raue K . Update on Multiple Endocrine Neoplasia Type 2: Focus on Medullary Thyroid Carcinoma. J Endocr Soc. 2018; 2(8):933-943. PMC: 6065486. DOI: 10.1210/js.2018-00178. View

Ceccherini I, Pasini B, Pacini F, Gullo M, Bongarzone I, Romei C . Somatic in frame deletions not involving juxtamembranous cysteine residues strongly activate the RET proto-oncogene. Oncogene. 1997; 14(21):2609-12. DOI: 10.1038/sj.onc.1201079. View

Ferrara R, Auger N, Auclin E, Besse B . Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer. J Thorac Oncol. 2017; 13(1):27-45. DOI: 10.1016/j.jtho.2017.10.021. View

Antonescu C, Suurmeijer A, Zhang L, Sung Y, Jungbluth A, Travis W . Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement. Am J Surg Pathol. 2015; 39(7):957-67. PMC: 4465992. DOI: 10.1097/PAS.0000000000000404. View

Drilon A, Hu Z, Lai G, Tan D . Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. Nat Rev Clin Oncol. 2017; 15(3):151-167. PMC: 7938338. DOI: 10.1038/nrclinonc.2017.175. View

Prescott J, Zeiger M . The RET oncogene in papillary thyroid carcinoma. Cancer. 2015; 121(13):2137-46. DOI: 10.1002/cncr.29044. View

Latteyer S, Klein-Hitpass L, Khandanpour C, Zwanziger D, Poeppel T, Schmid K . A 6-Base Pair in Frame Germline Deletion in Exon 7 Of RET Leads to Increased RET Phosphorylation, ERK Activation, and MEN2A. J Clin Endocrinol Metab. 2016; 101(3):1016-22. DOI: 10.1210/jc.2015-2948. View

10.

Schlumberger M, Jarzab B, Cabanillas M, Robinson B, Pacini F, Ball D . A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer. Clin Cancer Res. 2015; 22(1):44-53. DOI: 10.1158/1078-0432.CCR-15-1127. View

11.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

12.

Cordioli M, Moraes L, Bastos A, Besson P, Alves M, Delcelo R . Fusion Oncogenes Are the Main Genetic Events Found in Sporadic Papillary Thyroid Carcinomas from Children. Thyroid. 2016; 27(2):182-188. DOI: 10.1089/thy.2016.0387. View

13.

Gautschi O, Milia J, Filleron T, Wolf J, Carbone D, Owen D . Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. J Clin Oncol. 2017; 35(13):1403-1410. PMC: 5559893. DOI: 10.1200/JCO.2016.70.9352. View

14.

Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E . Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab. 2007; 93(3):682-7. DOI: 10.1210/jc.2007-1714. View

15.

Rosenzweig M, Ali S, Wong V, Schrock A, Laetsch T, Ahrens W . A case of advanced infantile myofibromatosis harboring a novel MYH10-RET fusion. Pediatr Blood Cancer. 2016; 64(7). DOI: 10.1002/pbc.26377. View

16.

Wells Jr S, Robinson B, Gagel R, Dralle H, Fagin J, Santoro M . Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2011; 30(2):134-41. PMC: 3675689. DOI: 10.1200/JCO.2011.35.5040. View

17.

Fox E, Widemann B, Chuk M, Marcus L, Aikin A, Whitcomb P . Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma. Clin Cancer Res. 2013; 19(15):4239-48. PMC: 4274128. DOI: 10.1158/1078-0432.CCR-13-0071. View

18.

Paratala B, Chung J, Williams C, Yilmazel B, Petrosky W, Williams K . RET rearrangements are actionable alterations in breast cancer. Nat Commun. 2018; 9(1):4821. PMC: 6240119. DOI: 10.1038/s41467-018-07341-4. View

19.

Carvalho D, Mackay A, Bjerke L, Grundy R, Lopes C, Reis R . The prognostic role of intragenic copy number breakpoints and identification of novel fusion genes in paediatric high grade glioma. Acta Neuropathol Commun. 2014; 2:23. PMC: 3938307. DOI: 10.1186/2051-5960-2-23. View

20.

Elisei R, Schlumberger M, Muller S, Schoffski P, Brose M, Shah M . Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013; 31(29):3639-46. PMC: 4164813. DOI: 10.1200/JCO.2012.48.4659. View